HOLLISTON, Mass., July 1, 2011 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today announced that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.
